Cargando…

(18)F-FDG PET-CT评估在接受自体造血干细胞移植的弥漫大B细胞淋巴瘤患者中的预后意义

OBJECTIVE: To evaluate the prognostic value of (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) in patients with diffuse large B cell lymphoma (DLBCL) undergoing autologous hematopoietic stem cell transplantation (auto-HSCT). METHODS: Forty-eight patients with DLB...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342905/
https://www.ncbi.nlm.nih.gov/pubmed/29779346
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.05.007
_version_ 1783555628196691968
collection PubMed
description OBJECTIVE: To evaluate the prognostic value of (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) in patients with diffuse large B cell lymphoma (DLBCL) undergoing autologous hematopoietic stem cell transplantation (auto-HSCT). METHODS: Forty-eight patients with DLBCL treated at Peking University Cancer Hospital between November 2010 and December 2014 were assessed. All patients underwent PET/CT scanning prior to or after auto-HSCT. Correlation analysis was done based upon patients characteristics, PET/CT scan results and survival. RESULTS: ①Among 48 patients, 27 was male, 21 female, median age was 43 (17–59) years old. ②Patients with negative pre-auto-HSCT PET/CT assessment demonstrated significantly better 3-year progression free survival (PFS) (87.1% vs 53.3%, χ(2)=7.02, P=0.019) and overall survival (OS) (90.3% vs 60.0%, χ(2)=6.51, P=0.022) than patients with positive pre-auto-HSCT PET/CT assessment. Three-year PFS (94.1% vs 30.0%, χ(2)=22.75, P=0.001) and OS (97.1% vs 40.0%, χ(2)=21.09, P=0.002) were also significantly different between patients with negative and positive post-auto-HSCT PET/CT assessment. ③Multivariate analysis indicated a significant association of PFS (HR=13.176, P=0.005) and OS (HR=20.221, P=0.007) with post-auto-HSCT PET/CT assessment. Number of prior treatment regimens was associated with PFS (HR=10.039, P=0.040). ④Harrell's C index revealed that the value of combined use of number of prior treatment regimens and post-auto-HSCT PET/CT assessment was superior to either one used alone in PFS (Harrell's C values were 0.976, 0.869 and 0.927 in combined use, number of prior treatment regimens and post-auto-HSCT PET/CT assessment, respectively), and the combined use of ECOG performance status and post-auto-HSCT PET/CT assessment significantly increased the Harrell's C index in OS (Harrell's C values were 0.973, 0.711 and 0.919 in combined use, ECOG performance status and post-auto-HSCT PET/CT assessment, respectively). CONCLUSION: Post-auto-HSCT PET/CT assessment is the main predictor of outcomes in DLBCL patients receiving auto-HSCT. Combined use of post-auto-HSCT PET/CT assessment and number of prior treatment regimens and ECOG performance status is a better prognostic tool in patients with DLBCL undergoing transplantation.
format Online
Article
Text
id pubmed-7342905
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73429052020-07-16 (18)F-FDG PET-CT评估在接受自体造血干细胞移植的弥漫大B细胞淋巴瘤患者中的预后意义 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To evaluate the prognostic value of (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) in patients with diffuse large B cell lymphoma (DLBCL) undergoing autologous hematopoietic stem cell transplantation (auto-HSCT). METHODS: Forty-eight patients with DLBCL treated at Peking University Cancer Hospital between November 2010 and December 2014 were assessed. All patients underwent PET/CT scanning prior to or after auto-HSCT. Correlation analysis was done based upon patients characteristics, PET/CT scan results and survival. RESULTS: ①Among 48 patients, 27 was male, 21 female, median age was 43 (17–59) years old. ②Patients with negative pre-auto-HSCT PET/CT assessment demonstrated significantly better 3-year progression free survival (PFS) (87.1% vs 53.3%, χ(2)=7.02, P=0.019) and overall survival (OS) (90.3% vs 60.0%, χ(2)=6.51, P=0.022) than patients with positive pre-auto-HSCT PET/CT assessment. Three-year PFS (94.1% vs 30.0%, χ(2)=22.75, P=0.001) and OS (97.1% vs 40.0%, χ(2)=21.09, P=0.002) were also significantly different between patients with negative and positive post-auto-HSCT PET/CT assessment. ③Multivariate analysis indicated a significant association of PFS (HR=13.176, P=0.005) and OS (HR=20.221, P=0.007) with post-auto-HSCT PET/CT assessment. Number of prior treatment regimens was associated with PFS (HR=10.039, P=0.040). ④Harrell's C index revealed that the value of combined use of number of prior treatment regimens and post-auto-HSCT PET/CT assessment was superior to either one used alone in PFS (Harrell's C values were 0.976, 0.869 and 0.927 in combined use, number of prior treatment regimens and post-auto-HSCT PET/CT assessment, respectively), and the combined use of ECOG performance status and post-auto-HSCT PET/CT assessment significantly increased the Harrell's C index in OS (Harrell's C values were 0.973, 0.711 and 0.919 in combined use, ECOG performance status and post-auto-HSCT PET/CT assessment, respectively). CONCLUSION: Post-auto-HSCT PET/CT assessment is the main predictor of outcomes in DLBCL patients receiving auto-HSCT. Combined use of post-auto-HSCT PET/CT assessment and number of prior treatment regimens and ECOG performance status is a better prognostic tool in patients with DLBCL undergoing transplantation. Editorial office of Chinese Journal of Hematology 2018-05 /pmc/articles/PMC7342905/ /pubmed/29779346 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.05.007 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
(18)F-FDG PET-CT评估在接受自体造血干细胞移植的弥漫大B细胞淋巴瘤患者中的预后意义
title (18)F-FDG PET-CT评估在接受自体造血干细胞移植的弥漫大B细胞淋巴瘤患者中的预后意义
title_full (18)F-FDG PET-CT评估在接受自体造血干细胞移植的弥漫大B细胞淋巴瘤患者中的预后意义
title_fullStr (18)F-FDG PET-CT评估在接受自体造血干细胞移植的弥漫大B细胞淋巴瘤患者中的预后意义
title_full_unstemmed (18)F-FDG PET-CT评估在接受自体造血干细胞移植的弥漫大B细胞淋巴瘤患者中的预后意义
title_short (18)F-FDG PET-CT评估在接受自体造血干细胞移植的弥漫大B细胞淋巴瘤患者中的预后意义
title_sort (18)f-fdg pet-ct评估在接受自体造血干细胞移植的弥漫大b细胞淋巴瘤患者中的预后意义
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342905/
https://www.ncbi.nlm.nih.gov/pubmed/29779346
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.05.007
work_keys_str_mv AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì
AT 18ffdgpetctpínggūzàijiēshòuzìtǐzàoxuègànxìbāoyízhídemímàndàbxìbāolínbāliúhuànzhězhōngdeyùhòuyìyì